Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2021)

ARS Pharmaceuticals' Amortization of Deferred Charges history spans 1 years, with the latest figure at $1000.0 for Q2 2021.

  • For Q2 2021, Amortization of Deferred Charges changed N/A year-over-year to $1000.0; the TTM value through Dec 2021 reached $2000.0, changed N/A, while the annual FY2021 figure was $2000.0, 93.55% down from the prior year.
  • Amortization of Deferred Charges for Q2 2021 was $1000.0 at ARS Pharmaceuticals, roughly flat from $1000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1000.0 in Q1 2021 and bottomed at $1000.0 in Q1 2021.